Management team.

Anki Malmborg Hager
Chief Executive Officer since 2014

Anki Malmborg Hager has a PhD in Immunotechnology and MSc in chemical engineering from the Faculty of Engineering at Lund University. Anki Malmborg Hager has also studied for an MBA with special focus on the pharmaceutical industry as well as executive training at Executive Foundation Lund.
Current appointments: Anki Malmborg Hager is a member of the Board of Avena Partners AB, DiaProst AB, Hager Consulting AB and Immunovia AB.
Previous appointments (last five years): Board member of Bulb Intelligence AB, Cantargia AB and WC Likvid AB. Managing Director of Sista versen 26366 AB.

Maria Agemark
Laboratory and Quality Manager since 2015

Maria Agemark has a Bachelor’s degree in molecular biology and a PhD in biochemistry from Lund University. Prior to her current position, Maria Agemark was employed as a research engineer at SenzaGen, and has previously worked as a research engineer and as a postdoctoral researcher at the Department of Immunotechnology at Lund University. Maria Agemark has also completed courses in management training.
Current appointments: Shareholder and board member of GFM
Förvaltning AB.
Previous appointments (last five years): Deputy board member of ApoGlyx AB.

Marianne Olsson
Chief Financial Officer since 2016

Marianne Olsson is an economist who received her education at Malmö Latinskola and has previously worked as a departmental economist, finance officer and most recently as Administration Manager at the Department of Immunotechnology at Lund University. Marianne Olsson has studied accounting at Lund University and has taken several internal and external management-related courses. In addition, Marianne Olsson has been a member of the board of directors at the Faculty of Engineering at Lund University and a member of the management team and institutional board of the Department of Immunotechnology.
Current appointments: None.
Previous appointments (last five years): None.

Stephen Smith
Intellectual Property counsel since 2017

Stephen Smith holds a PhD in neuroscience and a Master’s degree in biochemistry from Oxford University in England. Stephen Smith is also a European patent attorney at the European Patent Institute and patent attorney at the UK Patent Institute. Stephen Smith is a partner at Potter Clarkson and for more than 15 years has been advising companies across Europe on many issues including those related to intellectual property protection and product commercialization.
Current appointments: Stephen Smith is a partner at Potter Clarkson LLP, board member of Potter Clarkson AB and adviser to Immunovia AB.
Previous appointments (last five years): None.

Anna Chérouvrier Hansson
Chief Commercial Officer since 2017

Anna Chérouvrier Hansson holds a European Master‘s degree in Business Administration from Lund University and a Bachelor’s degree in Business Administration from the European Partnership of Business Schools, Groupe ESC Reims, France and Fachhochschule Reutlingen, Germany. Anna Chérouvrier Hansson has extensive experience in the pharmaceutical industry and has previously worked with commercialization and business development at a number of companies including Camurus AB and Invest in Skåne AB. In addition, Anna Chérouvrier Hansson has been one of four partners at Zitha Consulting AB, working on behalf of pharmaceutical companies and their commercialization strategies. Anna Chérouvrier Hansson has international employment experience and has previously worked in Denmark, Luxembourg and Germany.
Current appointments: Anna Chérouvrier Hansson is a partner and  board member
of Nordå Gård AB and board member of MVIC (Medicon Valley Inhalation Consortium).
Previous appointments (last five years): Deputy Board of Directors of The DMC Ambassador / Scandinavia AB, member of the Investment Committee in Innovationsbron AB and a leading postion in Invest in Skåne.